Enhancing quality of life as a goal for anticancer therapeutics

Sci Transl Med. 2016 Jun 22;8(344):344ed9. doi: 10.1126/scitranslmed.aag0382.

¹ Syril D. Pettit is the Executive Director of the ILSI, Health and Environmental Sciences Institute (HESI), Washington, DC 20005, USA. Email: spettit@hesiglobal.orgSteven E. Lipshultz is Pediatrician-in-Chief of Children's Hospital of Michigan; Chair of Pediatrics, Wayne State University School of Medicine; President of University Pediatricians; and Interim Director of Children's Research Center of Michigan, Detroit, MI 48201, USA; and Editor-in-Chief, Cardio-Oncology.Charles S. Cleeland is McCullough Professor of Cancer Research, Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.Samantha Roberts is Director of Scientific Affairs, Friends of Cancer Research, Washington, DC 20036, USA.Myrtle Davis is Chief, Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute, Bethesda, MD 20892, USA.Brian R. Berridge is Senior GSK Fellow and Head of Worldwide Animal Research Strategy, GlaxoSmithKline, King of Prussia, PA 19406, USA.Rebecca A. Kirch is Executive Vice President, Healthcare Quality and Value, National Patient Advocate Foundation, Washington, DC 20005, USA.

Abstract

Translational cancer research requires a quality-of-life-driven agenda.